ARTICLE
14 November 2024

The Prophecy: How Will The FDA Under The New Trump Administration Handle OPDP Letters? (Jeff And Dara's Version)

HP
Hyman, Phelps, & McNamara

Contributor

Hyman, Phelps & McNamara, the largest FDA-focused law firm in the U.S., specializes in comprehensive legal solutions for companies regulated by the FDA and related agencies like the DEA, CMS, and USDA. The firm assists with regulatory compliance, product lifecycle management, marketing compliance, and due diligence, offering practical, responsive, and client-focused legal strategies. With extensive experience across the food, drug, and medical device sectors, their team supports businesses throughout the supply chain, providing tailored guidance to management, scientists, and compliance officers.

We recently saw an interesting Instagram post aimed at Swifties disappointed in the election results. It noted that Tay Tay released four albums during the first Trump administration...
United States Food, Drugs, Healthcare, Life Sciences

We recently saw an interesting Instagram post aimed at Swifties disappointed in the election results. It noted that Tay Tay released four albums during the first Trump administration and only two during the Biden administration, so there's reason to hope for the next four years if one was despondent over the election. (One of the undersigned is an avowed metalhead and cannot attest to the accuracy of the statement because he was too lazy to ask his teenaged daughter.).

It got us thinking (dare we saying, having a prophecy?), how would the second Trump administration compare to the Biden administration when it comes to FDA OPDP warning letters and untitled letters for promotional issues? Our assumption was that using the first Trump administration as a baseline compared to the Biden administration would result in an inverse correlation to the above mentioned Taylor Swift output. (Thus proving that anything can be made to sound more intelligent when saying "inverse correlation" including a comparison of Taylor Swift albums and FDA letters.)

Much like Ms. Swift, we did something bad in assuming this. Like most of Taylor's dating choices, we were completely wrong. In fact, the number of letters issued by OPDP (both Warning Letters and Untitled Letters) were almost identical under the first Trump administration and the Biden administration to date. Under the first Trump administration, FDA issued 16 untitled letters and seven warning letters (almost, but not quite 22). Under the Biden administration, the numbers were 15 untitled letters and 4 warning letters.

So what does that mean going forward? We'd like to say that the past is perhaps predictive of the future, but given the potential involvement of Trump whisperers like RFK Jr, who is no fan of Big Pharma (or perhaps any Pharma), we simply don't know. While certain aspects of business regulation and other areas of FDA regulatory oversight are likely going to be loosened up under the new administration, companies should remain vigilant about their promotional review processes and should not assume that everything has changed. We know all too well how delicate this would be treated if this was a movie — all we can say is breathe, we may need to tolerate it but ask, are you ready for it?

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More